Latest News

National Cancer Institute Opens First Therapeutic Vaccine Trial for Chordoma Patients (US)

National Cancer Institute Opens First Therapeutic Vaccine Trial for Chordoma Patients

The National Cancer Institute has expanded an ongoing Phase I clinical trial of a therapeutic vaccine targeting the brachyury protein to include up to 10 patients with chordoma, a cancer that is defined by expression of brachyury.

About the Trial

Researchers at the National Cancer Institute (NCI) are conducting a Phase 1 clinical trial of a therapeutic vaccine, GI-6301, in patients with cancers known to express a protein called brachyury. Brachyury is sometimes over-expressed in a variety of important tumor types including breast, colon, lung, prostate cancers, and others, but is not generally found in normal tissues. Additionally and importantly, brachyury is also present in nearly 100% of chordomas and it has become a defining marker for the disease. The GI-6301 vaccine is intended to stimulate the immune system to fight cancer cells that express the brachyury protein.

The NCI Phase 1 trial of GI-6301, led by Dr. James Gulley, has completed the dose-escalation portion of the trial and has reached the maximum planned dose without any serious adverse reactions. Now the NCI is beginning to enroll a group of 10 patients at the highest dose. Originally, the trial was designed to enroll only patients with metastatic or unresectable locally recurrent cancers, not including chordoma. However, because chordomas nearly always express brachyury, the clinical protocol was recently modified to allow any patient with recurrent chordoma to be enrolled in the trial. This phase of the trial aims to (i) continue to assess the safety of the vaccine, (ii) test whether it causes an immune response to the brachyury protein, and (iii) to assess signs of clinical benefit.

The trial is taking place at the National Institutes of Health clinical center in Bethesda, MD. It involves injections of the vaccine every other week over the course of 7 visits, and then monthly until disease progression. The NCI will pay for transportation costs (including airfare) and a portion of lodging costs for patients enrolled in this study.  If you are interested in learning more about possibly enrolling in this study, please contact Christopher Heery, M.D. at heerycr@mail.nih.gov.

About the Treatment

GI-6301 is a therapeutic vaccine being developed through a Collaborative Research and Development Agreement between the National Cancer Institute and the biopharmaceutical company, GlobeImmune. Designed to stimulate the human immune system to fight cancer, GI-6301 is composed of heat-inactivated S. cerevisiae yeast that expresses human brachyury protein. This product candidate is the fifth of a novel class of yeast-based immunotherapeutics designed to stimulate immune responses to eliminate diseased cells.  Spanning cancer and infectious diseases, these products have been evaluated in ten different Phase 1 and Phase 2 clinical trials.  They have shown a good tolerability profile in clinical programs to date.  Over 400 subjects have been treated thus far, including some who have received monthly dosing for over four years.  Expected adverse events from these products are limited to redness, swelling and tenderness at the injection site, and mild, brief flu-like symptoms.

For eligibility criteria and more information about this trial visit http://clinicaltrials.gov/ct2/show/NCT01519817


News archive


May 2017

UK chordoma patient choose Prague for his PBT...UK's first high-energy proton beam machine in...New Malden Farmers Market supports Chordoma UK

April 2017

Spring 2017 update from Chordoma UK and...Emma Holloway and "Team Chordoma" raises some...Thank you to the Tanner TrustParis marathon runner Alex raises almost...Charlotte raises £900 for Chordoma UK...Another London Marathon run for CUK

October 2016

What has McDonald's & chordoma got in common?...

August 2016

Chordoma Biobank coordinator Clare Unwin...

June 2016

Clare Unwin Joins CUK / UCL Cancer Institute..

January 2016

Chordoma UK funds UCL Cancer Institute Biobank...2016 London Marathon team runners - Ed and...

November 2015

You've broken the £400,000 milestone!

October 2015

CUK founders Gerald & Susan Fitz-Gibbon at...Still plenty of time to register for the Milan...

September 2015

Well done to Aimee & Steve with another...What an amazing fund raising weekend it was...Guitars on The Beach - another huge success...

July 2015

Angela's travels with her tumour.....Sean runs the the 8.5 mile Sutton fun run and...Aimee and Steve run the "Nuts Challenge for...

April 2015

GlobeImmune Announces Opening of Randomized...

March 2015

Oliver and Kate run their first marathon for...Wow….. $1/2m raised so far!

January 2015

The simple math that explains why you may (or...A great start to 2015

December 2014

Sue Puddicombe does it again!With the state of cancer diagnosis a source of...John Baron MP, chairman of the All Party...John Baron MP hosts and addresses ‘Cancer52’...

November 2014

Updating James's Story........ Exceptional Wallace Collection fundraiser for...Chordoma UK receives a bequest of £10,000.00News from GlobeImmune Inc following their...

October 2014

Some facts, figures and a little trumpet...Hollywood here we come…..Lord Darzi formally unveils plans today to...Tim runs for Chordoma UK

September 2014

Central London Gallery Event...

August 2014

With a quite extraordinary result for...Sarah Holdsworth - runs like mad for Chordoma...

June 2014

Dinner Dance, Ferrari's Country Hotel,...Reception at St James's PalaceFunds are needed NOW to develop new therapies...Raising funds for research and awareness...

May 2014

CYCLING FROM LONDON TO NICE FOR CHORDOMA UK...

April 2014

Getting close to £100k !

March 2014

RAT RACE DIRTY WEEKEND. Ginny Major goes for it!The LONDON MARATHON.. Freddie, Joanne and...HAPPY BIRTHDAY TO US, HAPPY BIRTHDAY TO US.....Plans now being made for the Great River Race...Lots happening this spring.....

September 2013

NEW CHORDOMA UK WRISTBANDS AVAILABLE.ChordomaUK participating in London's 21 mile...

August 2013

Blood transfusions during cancer treatment... ...Imatinib.. (Glivec in the UK) often talked...New Initiative Launches to Organize the UK...Welcome Lisa....

June 2013

Researchers at Oxford University Hospitals are...Identification of repurposed small molecule...National Cancer Institute Opens First...Chordoma UK now joined the Cancer52 Alliance...Walkers raise over £2,500.00 for Chordoma UK

April 2013

Mail on Sunday article raises awareness

February 2013

Chi-chi Nwanoku & friends Chamber Concert benefitResearch - what have we achieved so far
Get involved!

Help us raise money to fund more research into Chordoma